This article reviews the results of the rigorously-controlled clinical trial focusing on the use of copolymer-1 in the treatment of patients with relapsing-remitting MS.
Copolymer-1 (Copaxone[R]), is an acetate salt resulting from a mixture of synthetic polypeptides composed of the four amino acids L-alanine L-glutamic acid, L-lysine and L-tyrosine.
Copolymer-1 was first synthesized in 1967, and was studied extensively in animal models.
Copolymer-1 was studied by Johnson et al in 1995, in a multicenter, phase III trial of patients with relapsing-remitting multiple sclerosis.
Patients who had been treated with copolymer-1 or any other immuno-suppressive therapy, chemotherapy or lymphoid irradiation were also excluded.
Nurses are in a unique position to give patients taking copolymer-1 advice about medication administration and storage, adverse effects, psychological/psychosocial issues, as well as tips for proper administration.